Sodium tanshinone IIA sulfonate depresses angiotensin IIinducedcardiomyocyte hypertrophy through MEK/ERKpathway

다국어 초록 (Multilingual Abstract)

Cardiomyocyte hypertrophy is a major cause of
morbidity and mortality worldwide. The aim of this
study is to determine the effects of sodium tans -
hinone IIA sulfonate (STS) on cardiomyocyte hypertrophy
induced by angiotensin II (Ang II) in vivo
and in vitro. In long-term treatment, adult Wistar rats
were infused with Ang II for three weeks via osmotic
mini-pumps and some of them were given intragas -
trically of STS. Left ventricle was isolated; the ratio
of left ventricular weight to body weight and systolic
blood pressure (SBP) were determined and heart
morphometry was assessed after hematoxylin and
eosin staining. Results indicated STS inhibited Ang
II-induced increases in myocyte diameter and
decreased the LVW/BW ratio independent of decreasing
systolic blood pressure. In vitro, treatment
of cultured cardiomyocytes with STS inhibited Ang
II-induced increase in cell size, protein synthesis,
ANP expression, activation of extracellular signalregulated
kinase (ERK) and ERK kinase (MEK). Then
we reexamined the mechanism of STS-induced antihypertrophic
effects. Results revealed MEK inhibitor
U0126 (20 µM) markedly enhanced STS-induced
depressions in [3H]leucine incorporation and ANP
expression. In conclusion, MEK/ERK pathway plays
a significant role in the anti-hypertrophic effects of
STS.

참고문헌 (Reference)

1 Kennedy RA, "Using U0126 to dissect the role of the extracelular signal-regulated kinase 1/2 (ERK1/2) cascade in the regulation of gene expression by endothelin-1 in cardiac myocytes." 41 : 236-247, 2006

2 Sven W, "The role of the AT1 receptor in the cardiovascular continuum" 6 : h3-h9, 2004

3 Wassmann S, "The role of the AT1 receptor in the cardiovascular continnum" 6 : h3-h9, 2004

4 Hayakawa H, "The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension" 29 : 235-241, 1997

5 Dostal DE, "The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function?" 85 : 643-650, 1999

6 Bueno OF, "The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice" 19 : 6341-6350, 2000

7 Wollert KC, "Survival after myocardial infarction in the rat Role of tissue angio-tensin-converting enzyme inhibition" 2457-67, circulation1994;90

8 Takeishi Y, "Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch" 33 : 1637-1648, 2001

9 Takahashi K, "Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells" 64 : 745-750, 2002

10 Sugden PH, "Signalling pathways in cardiac myocyte hy-pertrophy" 33 : 611-622, 2001

11 Ptashne M, "Signal transduction: imposing specificity on kinases" 299 : 1025-1027, 2003

12 Maller JL, "Signal transduction: fishing at the cell surface" 300 : 594-595, 2003

13 Lijnen P, "Renin-Angiotensin System, Hypertrophy and Gene Expression in Cardiac Myocytes" 31 : 949-970, 1999

14 Hannan RD, "Regulation of ribosomal DNA transcription during contraction-induced hypertrophy of neonatal cardiomyocytes" 271 : 3213-3220, 1996

15 Sen S, "Regression of cardiac hypertrophy" 87-93, amjmed1983;75

16 Shih NL, "Reactive oxygen species modulate angiotensin II-induced beta-myosin heavy chain gene expression via Ras/Raf/extracellular signal-regulated kinase pathway in neonatal rat cardiomyocytes" 283 : 143-148, 2001

17 Seko Y, "Pulsatile stretch activates mitogen-activated protein kinase (MAPK) family members and focal adhesion kinase (p125(FAK)) in cultured rat cardiac myocytes" 259 : 8-14, 1999

18 Frias MA, "Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: A role in cardiac hypertrophy" 73 : 57-65, 2007

19 Levy D, "Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study" 1561-6,

20 Miyazaki H, "Intracellular signaling pathways of angiotensin II receptor type I involved in the development of cardiovascular diseases" 56 : 1906-1911, 1998

21 Thorburn J, "Inhibition of a signaling pathway in cardiac muscle cells by active mitogen-activated protein kinase kinase" 6 : 1479-1490, 1995

22 Favata MF, "Identification of a novel mitogen inhibitor of mitogen-activated protein kinase kinase" 273 : 18623-18632, 1998

23 Frey N, "Hypertrophy of the heart : a new therapeutic target?" 109 : 1580-1589, 2004

24 Force T, "Growth factors and mitogen-activated protein kinases" 31 : 152-161, 1998

25 Tang W, "Experimental study on prevent effect of tanshinone on injury of ischemia-reperfusion of heart" 16 : 202-204, 1996

26 Kim L, "Characterization of MAP kinase and PKC isoform and effect of ACE inhibition in hypertrophy Sodium tanshinone IIA sulfonate and cardiomyocyte hypertrophy.73in vivo" 277 : 1808-1816, 1999

27 Cohn JN, "Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf on an international forum on cardiac remodelling" 35 : 569-582, 2000

28 Solit DB, "BRAF mutation predicts sensitivity to MEK inhibition" 439 : 358-362, 2005

29 Miao CY, "Arterial remodeling in chronic sinoaortic-denervated rats" 37 : 6-15, 2001

30 Kagiyama S, "Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense" 106 : 909-912, 2002

31 Baker KM, "Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells" 610-8,

32 Pinzar E, "Angiotensin II induces tyrosine nitration and activation of ERK1/2 in vascular smooth muscle cells" 579 : 5100-5104, 2005

33 Fischer TA, "Activation of cardiac c-Jun NH(2)-terminal kinases and p38-mitogen-activated protein kinases with abrupt changes in hemodynamic load" 37 : 1222-1228, 2001